{"nctId":"NCT00546754","briefTitle":"BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)","startDateStruct":{"date":"2007-05-01","type":"ACTUAL"},"conditions":["Hypertension"],"count":808,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: losartan potassium (+) hydrochlorothiazide"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Comparator: Valsartan (+) Hydrochlorothiazide"]}],"interventions":[{"name":"losartan potassium (+) hydrochlorothiazide","otherNames":[]},{"name":"Comparator: Valsartan (+) Hydrochlorothiazide","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* An Adult Patient 18 to 75 Years Of Age\n* Patient with essential hypertension receiving an antihypertensive agent in monotherapy for at least 4 weeks for whom the antihypertensive agent can (and will) be discontinued and whose blood pressure is not controlled:\n* Either systolic or diastolic blood pressure \\> 140/90 mm Hg up to 180/110 mm Hg (inclusive)\n* Either systolic or diastolic blood pressure \\> 130/80 mm Hg up to 160/100 mm Hg (inclusive) for diabetic patients\n* Patient is male or a female who is highly unlikely to conceive as she falls into one of the categories listed below:\n\n  * Surgically sterilized female\n  * Postmenopausal female \\> 45 years of age with \\> 2 years since her last menses\n  * Non-sterilized pre-menopausal female who agrees to: (1) use 2 adequate methods of contraception to prevent pregnancy \\[either 2 barrier methods or a barrier method plus a hormonal method\\]; or (2) abstain from heterosexual activity throughout the study starting with Visit 1 and for 14 days after the last dose of study medication; or (3) only engage in heterosexual activity with surgically sterilized male partner(s) throughout the study starting with Visit 1 and for 14 days after the last dose of study medication\n  * Patient judged to be in otherwise good, stable health on the basis of medical history and physical examination\n\nExclusion Criteria:\n\n* Known secondary hypertension of any aetiology (e.g., uncorrected renal artery stenosis, malignant hypertension, or hypertensive encephalopathy)\n* Patient Needing An Initiation Of A Lipid Lowering Agent Or A Modification Of His Lipid Therapy At Visit 1 Or During The Study Period (12 Weeks)\n* Patient taking allopurinol\n* Patient Previously Shown To Be Intolerant To Any Component Of Losartan Valsartan, Or HCTZ Or With A Documented History Of Angioedema/Anaphylaxis\n* Patient With Confirmed Clinically Significant Renal Or Hepatic Dysfunction And/Or Electrolyte Imbalance Laboratory Test Within The Last 3 Months Prior To Visit 1: Serum Creatinine \\> 130 Umol/L Or Creatinine Clearance \\< 45 Ml/Min, Aspartate transaminase (AST) \\> 2 Times Above The Normal Range, Alanine transaminase (ALT) \\> 2 Times Above The Normal Range, Serum Potassium \\< 3.5 Or \\> 5.5 Meq/L\n* Patient with osteoarthritis who has undergone hip or knee replacement within the last 4 months\n* Patient with chronic inflammatory conditions such as rheumatoid arthritis, lupus, inflammatory bowel disease and those that need a chronic inflammatory therapy such as prednisone or other steroid agents\n* Patient with symptomatic heart failure (classes 3 and 4)\n* Patient with a history of stroke within the last 6 months\n* Patient with coronary heart disease: has undergone percutaneous coronary angioplasty, has had coronary artery bypass, has had past myocardial infarction, all that occurred less than 6 months prior to visit 1 or has unstable angina\n* Patient having participated in an investigational drug program in the last 30 days (prior to Visit 1)\n* Unable or unwilling to comply with the protocol, therefore likely to leave the trial before its completion\n* Patient intends to move or to vacation away from home during the course of the study which would interfere with the scheduled visits.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Change in Systolic Blood Pressure From Baseline to Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.7","spread":"14.70"},{"groupId":"OG001","value":"-18.2","spread":"13.84"}]}]}]},{"type":"SECONDARY","title":"Change in Diastolic Blood Pressure From Baseline to Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.4","spread":"9.35"},{"groupId":"OG001","value":"-9.1","spread":"9.16"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Achieving Target Blood Pressure at Week 6","description":"Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) at week 6","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"241","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]}]},{"type":"PRIMARY","title":"Change in Systolic Blood Pressure From Baseline to Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.9","spread":"13.79"},{"groupId":"OG001","value":"-20.8","spread":"13.61"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Achieving Target Blood Pressure at Week 12","description":"Number of Patients Achieving Target Blood Pressure (\\<140/90 mm Hg and \\<130/80 mm Hg for diabetics) at week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"278","spread":null},{"groupId":"OG001","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Achieve Target Blood Pressure","description":"Time to achieve the target blood pressure (\\<140/90 mmHg and \\<130/80 mmHg for diabetics)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.3","spread":"1.44"},{"groupId":"OG001","value":"57.3","spread":"1.24"}]}]}]},{"type":"SECONDARY","title":"Change in Uric Acid From Baseline to Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"53.12"},{"groupId":"OG001","value":"21.7","spread":"55.09"}]}]}]},{"type":"PRIMARY","title":"Change in Diastolic Blood Pressure From Baseline to Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"9.28"},{"groupId":"OG001","value":"-10.5","spread":"9.58"}]}]}]},{"type":"SECONDARY","title":"Change in Uric Acid From Baseline to Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"57.02"},{"groupId":"OG001","value":"29.9","spread":"64.79"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"26.21"},{"groupId":"OG001","value":"0.6","spread":"6.60"}]}]}]},{"type":"SECONDARY","title":"Change in Serum Highly Sensitive C-reactive Protein From Baseline to Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"8.05"},{"groupId":"OG001","value":"0.5","spread":"7.20"}]}]}]},{"type":"SECONDARY","title":"Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"21.20"},{"groupId":"OG001","value":"-0.1","spread":"24.71"}]}]}]},{"type":"SECONDARY","title":"Change in Gamma-Glutamyl Transpeptidase (Gamma-GT) From Baseline to Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"21.44"},{"groupId":"OG001","value":"-0.0","spread":"24.45"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":425},"commonTop":["C-Reactive protein increased","Headache","Dizziness","Abdominal pain upper","Blood potassium increased"]}}}